Metformin inhibits cytokine-induced nuclear factor κB activation via AMP-activated protein kinase activation in vascular endothelial cells

Hypertension

Volumn 47, Issue 6, 2006, Pages 1183-1188

  Hattori, Yoshiyuki ^a   Suzuki, Kunihiro ^a   Hattori, Sachiko ^a   Kasai, Kikuo ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Cell adhesion molecules; Diabetes mellitus; Endothelium

Indexed keywords

3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; 5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; ACETYL COENZYME A CARBOXYLASE; CELL ADHESION MOLECULE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; I KAPPA B; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; METFORMIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PHOSPHOACETYLCOENZYME A CARBOXYLASE; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; 5 AMINO 4 IMIDAZOLECARBOXAMIDE; 5' AMP ACTIVATED PROTEIN KINASE; 5'-AMP-ACTIVATED PROTEIN KINASE; AICA RIBONUCLEOTIDE; CCL2 PROTEIN, HUMAN; CYTOKINE; DRUG DERIVATIVE; ENZYME INHIBITOR; MEMBRANE PROTEIN; MESSENGER RNA; MULTIENZYME COMPLEX; PROTEIN SERINE THREONINE KINASE; RIBONUCLEOTIDE;

ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; UMBILICAL VEIN; BIOSYNTHESIS; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY;

AMINOIMIDAZOLE CARBOXAMIDE; CELLS, CULTURED; CHEMOKINE CCL2; CYTOKINES; ENDOTHELIAL CELLS; ENZYME ACTIVATION; ENZYME INHIBITORS; HUMANS; I-KAPPA B KINASE; I-KAPPA B PROTEINS; MEMBRANE GLYCOPROTEINS; METFORMIN; MULTIENZYME COMPLEXES; NF-KAPPA B; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; RIBONUCLEOTIDES; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33744976813     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000221429.94591.72     Document Type: Article

References (18)

1. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854-865.
2. Caballero AE, Delgado A, Aguilar-Salinas CA, Herrera AN, Castillo JL, Cabrera T, Gomez-Perez FJ, Rull JA. The differential effects of metformin on markers of endothelial activation and inflammation in subjects with impaired glucose tolerance: a placebo-controlled, randomized clinical trial. J Clin Endocrinol Metab. 2004;89:3943-3948.
3. De Jager J, Kooy A, Lehert P, Bets D, Wulffele MG, Teerlink T, Scheffer PG, Schalkwijk CG, Donker AJ, Stehouwer CD. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial. J Intern Med. 2005;257:100-109.
4. Hardie DG, Carling D, Carlson M. The AMP-activated/SNF1 protein kinase subfamily: metabolic sensors of the eukaryotic cell? Annu Rev Biochem. 1998;67:821-855.
5. Brand K, Page S, Rogler G, Bartsch A, Brandl R, Knuechel R, Page M, Kaltschmidt C, Baeuerle PA, Neumeier D. Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. J Clin Invest. 1996;97:1715-1722.
6. Iiyama K, Hajra L, Iiyama M, Li H, DiChiara M, Medoff BD, Cybulsky MI. Patterns of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 expression in rabbit and mouse atherosclerotic lesions and at sites predisposed to lesion formation. Circ Res. 1999;85:199-207.
7. Cybulsky MI, Gimbrone MA Jr. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science. 1991;251:788-791.
8. Boring L, Gosling J, Cleary M, Charo IF. Decreased lesion formation in CCR2 -/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature. 1998;394:894-897.
9. Collins T, Cybulsky MI. NF-κB: pivotal mediator or innocent bystander in atherogenesis? J Clin Invest. 2001;107:255-264.
10. Corton JM, Gillespie JG, Hawley SA, Hardie DG. 5-aminoimidazole-4- carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells? Eur J Biochem. 2002;229:558-565.
11. Hattori Y, Suzuki M, Hattori S, Kasai K. Vascular smooth muscle cell activation by glycated albumin (Amadori adducts). Hypertension. 2002;39:22-28.
12. Kamata H, Manabe T, Oka S, Kamata K, Hirata H. Hydrogen peroxide activates IκB kinases through phosphorylation of serine residues in the activation loops. FEBS Lett. 2002;519:231-237.
13. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001;108:1167-1174.
14. Musi N, Hirshman MF, Nygren J, Svanfeldt M, Bavenholm P, Rooyackers O, Zhou G, Williamson JM, Ljunqvist O, Efendic S, Moller DE, Thorell A, Goodyear LJ. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes. 2002;51:2074-2081.
15. Pierce JW, Schoenleber R, Jesmok G, Best J, Moore SA, Collins T, Gerritsen ME. Novel inhibitors of cytokine-induced IκBα phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J Biol Chem. 1997;272:21096-21103.
16. Giri S, Nath N, Smith B, Viollet B, Singh AK, Singh I. 5-aminoimidazole-4-carboxamide-1-β-4-ribofuranoside inhibits proinflammatory response in glial cells: a possible role of AMP-activated protein kinase. J Neurosci. 2004;24:479-487.
17. Lee SH, Kwon KI. Pharmacokinetic-pharmacodynamic modeling for the relationship between glucose-lowering effect and plasma concentration of metformin in volunteers. Arch Pharm Res. 2004;27:806-810.
18. Ruderman N, Prentki M. AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome. Nat Rev Drug Discov. 2004;3:340-351.